Navigation Links
Amira Pharmaceuticals Announces IND Submission for Novel LPA1 Antagonist, AM152, for Potential Use in Fibrotic Diseases
Date:9/27/2010

SAN DIEGO, Sept. 27 /PRNewswire-FirstCall/ -- Amira Pharmaceuticals, Inc. announced today that it has submitted an Investigational New Drug (IND) application to the US Food and Drug Administration (FDA) for AM152, a novel LPA1 antagonist.  If accepted, the IND will enable Amira to begin Phase 1 safety studies with the compound in healthy subjects.

"We believe the pre-clinical data obtained to date for AM152 demonstrate characteristics which warrant further studies in humans to determine its potential utility in various fibrotic diseases," said Isabelle DeArmond, Vice President, Clinical Development. "The safety and pharmacokinetic data obtained from Phase 1 studies are an important first step in the clinical investigation of this program."

Added Bob Baltera, Chief Executive Officer, "We are extremely excited to reach this point with our LPA1 program. There have recently been numerous papers published describing the novel biology of the LPA1 receptor and how it relates to abnormal fibrotic processes.  We have worked hard to develop this program and look forward to learning more about this potential therapeutic candidate in a clinical setting."

While there are no LPA1 selective antagonists approved for therapeutic use, there is a strong scientific rationale for this target to be a novel treatment in various fibrotic diseases, including scleroderma and idiopathic pulmonary fibrosis.

About Amira

Founded in 2005 and headquartered in San Diego, Amira Pharmaceuticals is a small molecule pharmaceutical company focused on the discovery and early development of new drugs to treat inflammatory disease. Our discovery team is building on unparalleled insights into bioactive lipid pathways and complex signaling processes controlling many conditions including asthma, chronic obstructive pulmonary disease, cardiovascular and fibrotic diseases.  Amira has a partnership with GlaxoSmithKline for the development of FLAP (5-li
'/>"/>

SOURCE Amira Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Amira Pharmaceuticals Named One of Most Promising Biotech Companies by FierceBiotechs Annual Fierce 15
2. Visage Imaging Releases Amira 5.3
3. Amira Announces AM103 and AM803 Patent Grant in the United Kingdom
4. Amira Announces Second DP2 Antagonist Patent Grant in the United Kingdom
5. Anti-Fibrotic Data from Amira Pharmaceuticals LPA1 Receptor Antagonist Program Published in the British Journal of Pharmacology
6. Amira Pharmaceuticals Announces Efficacy of LPA1 Antagonist in a Preclinical Model of Scleroderma
7. Amira Pharmaceuticals Announces Initial Positive Phase 1 Clinical Data for AM461, A Back-Up to Amiras Lead DP2 Antagonist, AM211
8. Amira Pharmaceuticals Submits IND for Second DP2 Antagonist, AM461
9. Keryx Biopharmaceuticals to Present at JMP Securities Healthcare Conference
10. Abbott and Reata Pharmaceuticals Announce Agreement to Develop and Commercialize Bardoxolone Methyl for Chronic Kidney Disease Outside the U.S.
11. Lotus Pharmaceuticals Announces Two Senior Management Appointments
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... 18, 2014 Research and Markets ... the "Micro Market Monitor: North American Dermatology ... http://photos.prnewswire.com/prnh/20130307/600769 ... steadily, which has resulted in fueling the overall ... main purpose of these dermatology devices is to ...
(Date:12/19/2014)... -- Capnia, Inc. (NASDAQ: CAPN ), ... on its proprietary Sensalyze™ Technology Platform for precision ... for the third quarter and nine months ended ... of our initial public offering (IPO), we are ... CoSense® commercial launch," said Anish Bhatnagar, M.D., Chief ...
(Date:12/19/2014)... , Dec. 18, 2014 Since last ... the site now known as the leading online black ... seen explosive growth in its offering of drugs and ... Alliance show the takedowns did succeed in lowering the ... last review of the markets in August. But some ...
Breaking Medicine Technology:Micro Market Monitor: North American Dermatology Diagnostic Devices Market 2Micro Market Monitor: North American Dermatology Diagnostic Devices Market 3Capnia Reports Third Quarter 2014 Financial Results 2Capnia Reports Third Quarter 2014 Financial Results 3Capnia Reports Third Quarter 2014 Financial Results 4Capnia Reports Third Quarter 2014 Financial Results 5Capnia Reports Third Quarter 2014 Financial Results 6Capnia Reports Third Quarter 2014 Financial Results 7Capnia Reports Third Quarter 2014 Financial Results 8Post Silk Road - Another Online Drug Den Now Dominates the DarkNet 2Post Silk Road - Another Online Drug Den Now Dominates the DarkNet 3
... Mass., May 9, 2011 Boston Scientific Corporation (NYSE: ... international launch of its Expect™ Endoscopic Ultrasound Aspiration Needle, ... malignancies in organs adjacent to the gastrointestinal tract.  The ... earlier this year and is being marketed in the ...
... Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR ... the position of vice president of legal affairs. ... stage biopharmaceutical company, Elona,s legal, regulatory and business expertise will ... Katkin, president and CEO of Avanir. "The executive team and ...
Cached Medicine Technology:Boston Scientific Begins U.S. and International Launch of Expect™ Endoscopic Ultrasound Aspiration Needle 2Boston Scientific Begins U.S. and International Launch of Expect™ Endoscopic Ultrasound Aspiration Needle 3Boston Scientific Begins U.S. and International Launch of Expect™ Endoscopic Ultrasound Aspiration Needle 4Avanir Pharmaceuticals Announces Appointment of Elona Kogan, Esq. as Vice President of Legal Affairs 2
(Date:12/19/2014)... 18, 2014 (HealthDay News) -- A new study suggests ... to severe hot flashes and night sweats -- and ... Hot flashes are common during menopause, affecting about 60 ... affect women after menopause, since they then face a ... findings suggest women who exhibit moderate or severe menopausal ...
(Date:12/19/2014)... 2014 (HealthDay News) -- Traveling through the same U.S. ... to three others within a four-hour time span, illustrating ... report shows. "The exposures in this report were ... an international terminal, highlighting the fact that measles is ... an infectious disease specialist at the U.S. Centers for ...
(Date:12/17/2014)... Dr. Myo Nwe is the co-author of a ... Future” and co-founder of the Ace Medical Weight Loss Center ... a broad look at the industry of weight loss, and ... On film and in television shows, however, she says the ... aspects and played for basic laughs, which she believes impacts ...
(Date:12/17/2014)... CA (PRWEB) December 17, 2014 A group ... Center for Longevity, today, in reaction to a recent statement ... science of brain training and derogated the efficacy of all ... they agreed with the parts of the center’s statement critical ... believed the center had also overstated its case, in a ...
(Date:12/17/2014)... December 17, 2014 Project Veritas is ... brought videos of MIT economist and Obamacare architect Jonathan ... James O’Keefe conducted the interview, which is being distributed ... there was intentional mislabeling in the Affordable Care Act ... bill: A two-hundred-and-fifty billion dollar per year tax grab. ...
Breaking Medicine News(10 mins):Health News:Severe Hot Flashes During Menopause May Raise Hip Fracture Risk Later: Study 2Health News:Arriving Now at Gate 42: Measles 2Health News:Arriving Now at Gate 42: Measles 3Health News:Obesity Should Not Be a Hollywood Punchline, Weight Loss Doc Says 2Health News:Scientists to Stanford: Research Shows Brain Exercises Can Work 2Health News:Scientists to Stanford: Research Shows Brain Exercises Can Work 3Health News:Scientists to Stanford: Research Shows Brain Exercises Can Work 4Health News:Project Veritas: James O’Keefe Interviews the Man Who Discovered Jonathan Gruber Videos 2
... activity, and it is the kind of music but the ... ,The findings, published ahead of print in Heart, are based ... men and women, taken before and while they listened to ... were trained musicians, who had been playing instruments for at ...
... to provide protection against lung cancer, according to the ... be responsible are plant-derived compounds known as phytoestrogens found ... fruits and vegetables, the report from the University of ... compounds have been shown to have a protective effect ...
... protein has helped bald mice to get fur on the ... men., ,Catherine C. Thompson and colleagues at Johns Hopkins ... as Hairless, which encodes a protein that is essential for ... mutations in the Hairless gene, hair growth is initially normal. ...
... Anbumani Ramadoss today fired another salvo at Medical Council of India ... of mafias over such a regulatory body was // a ... body and the government has no say in its functioning. What ... ,He said a cleansing process of the councils was ...
... living with HIV/AIDS in Manipur have hope at hand ... specialised clinics for their care and treatment//.,The Nobel prize-winning ... signed a memorandum of understanding with the Manipur government ... HIV/AIDS. ,The Dutch chapter of the MSF ...
... suffer from osteoporosis from loss of bone mass, there may ... shows that it can help improve bone mass in women ... of the principal recommendations for preventing and treating the loss ... isn’t always possible, particularly for the frail., ,An experimental ...
Cached Medicine News:Health News:Taking Music Lesson To Reduce Stress 2Health News:Specialized Clinics For Manipur's AIDS Patients 2
... ORTHOSET Radiopaque Bone Cement consists ... a sterile,ampule containing bone cement ... and a sterile polyethylene bag,containing ... peelable pouch. The interiors of ...
... Radiopaque Bone Cement consists of ... sterile,ampule containing bone cement liquid ... a sterile polyethylene bag,containing bone ... pouch. The interiors of the ...
A low viscosity type of bone cement, intended for syringe or cement gun application....
Antibiotics (Gentamicin) loaded, low viscosity bone cement for syringe use with an average setting time of approx. 7-9 Min., 41.6g of powder and 16.4g of liquid....
Medicine Products: